Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia

Who May Qualify: - Voluntary participation with written willing to sign a consent form signed by the participant or a legal guardian; willingness to comply with all study procedures. - Age 14 to 60 years at screening, no gender restriction. - Diagnosis of acute monocytic leukemia according to the 2016 WHO classification, excluding acute promyelocytic leukemia. - No history of severe allergic reactions. - Liver function: ALT and AST ≤ 2.5 × upper limit of normal (ULN); total bilirubin ≤ 2 × ULN. - Renal function: serum creatinine ≤ 1.5 × ULN - No uncontrolled infection or severe psychiatric disorder. - You should be able to carry out daily activities with 0 level of ability (ECOG 0)-3; life expectancy ≥ 4 months. Who Should NOT Join This Trial: - Known hypersensitivity or contraindication to any study drug. - Pregnancy or lactation. - Active infection. - Long-term smoking or alcohol abuse that may interfere with study outcome evaluation. - Psychiatric illness or other condition that prevents willing to sign a consent form or compliance with study procedures. - Major organ surgery within 6 weeks prior to enrollment. - Abnormal liver function: total bilirubin \> 2× ULN, ALT/AST \> 2.5 × ULN; abnormal renal function: serum creatinine \> 1.5 × ULN. - Any condition deemed unsuitable for the study by the investigator (e.g., poor compliance, substance abuse). Always talk to your doctor about whether this trial is right for you.